The American Society for Clinical Oncology annual meeting doesn't start until the end of this month, but investors will get a little sneak peek of what to expect when abstracts for the meeting are released at 5 p.m. Eastern on Wednesday.
In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss what they're looking forward to seeing at ASCO, including AstraZeneca's (NYSE:AZN) phase 2 data for its PARP inhibitor olaparib used alone or in combination with cediranib in patients with ovarian cancer, Johnson & Johnson (NYSE:JNJ) and Pharmacyclics' (NASDAQ:PCYC) phase 3 data testing Imbruvica verse GlaxoSmithKline's (NYSE:GSK) Arzerra in elderly CLL patient, Incyte's (NASDAQ:INCY) data on Jakafi in pancreatic cancer, and others.
Invest before it hits mainstream
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980s, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in the late 1990s, when it was nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play" and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.
Brian Orelli has no position in any stocks mentioned. David Williamson owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.